Drugs / SNP-630
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04808154 | Jul → Aug 2021 | metabolic dysfunction-associated steatohepatitis | Sinew Pharma Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-19 | Sinew Pharma Inc. | Results 欣耀在美發表脂肪肝炎新藥臨床數據 同步尋求授權 sinewpharma.com ↗
SNP-630 的有效代謝物已完成第二期臨床試驗，共收 36 名受試者並分成高、低兩劑量組，依據期中分析結果顯示，在臨床療效指標與未服藥前比較，呈現顯著治療效果，順利達成治療脂肪肝炎的目標。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-19 | Sinew Pharma Inc. | 欣耀在美發表脂肪肝炎新藥臨床數據 同步尋求授權 sinewpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNP-630 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04808154 ↗ |
| Route | Oral | “oral SNP-630 at a dose of 720 mg” NCT04808154 ↗ |